Summarized by Masters of Longevity from Sofinnova Partners.
A biotech update describing a Phase 1 clinical study of an oral small‑molecule TREM2 modulator, outlining safety, CNS exposure, and biomarker activity.
Key Takeaways
- Repeated dosing produced dose-dependent reductions in soluble TREM2 in CSF and plasma.
- The drug showed strong CSF exposure and similar pharmacokinetics in younger and elderly participants.
- No serious adverse events occurred and most adverse events were reported as mild.
